Avidity Biosciences Inc (NASDAQ: RNA) is 6.36% higher on its value in year-to-date trading and has touched a low of $21.51 and a high of $56.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RNA stock was last observed hovering at around $30.68 in the last trading session, with the day’s gains setting it 0.25%.
Currently trading at $30.93, the stock is 11.56% and 4.01% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.12 million and changing 0.81% at the moment leaves the stock -18.46% off its SMA200. RNA registered 28.02% gain for a year compared to 6-month loss of -33.78%. The firm has a 50-day simple moving average (SMA 50) of $29.7372 and a 200-day simple moving average (SMA200) of $37.932674.
The stock witnessed a -3.64% gain in the last 1 month and extending the period to 3 months gives it a 2.66%, and is 20.07% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.51% over the week and 8.20% over the month.
Avidity Biosciences Inc (RNA) has around 391 employees, a market worth around $3.72B and $10.90M in sales. Profit margin for the company is -2957.72%. Distance from 52-week low is 43.79% and -44.77% from its 52-week high. The company has generated returns on investments over the last 12 months (-22.57%).
with sales reaching $2.62M over the same period.The EPS is expected to shrink by -32.24% this year, but quarterly earnings will post -23.41% year-over-year. Quarterly sales are estimated to shrink -25.92% in year-over-year returns.
337.0 institutions hold shares in Avidity Biosciences Inc (RNA), with institutional investors hold 113.74% of the company’s shares. The shares outstanding are 119.89M, and float is at 111.14M with Short Float at 15.81%. Institutions hold 108.02% of the Float.
The top institutional shareholder in the company is FMR LLC with over 16.16 million shares valued at $660.1 million. The investor’s holdings represent 15.1121 of the RNA Shares outstanding. As of 2024-06-30, the second largest holder is PRICE T ROWE ASSOCIATES INC /MD/ with 10.92 million shares valued at $445.94 million to account for 10.2093 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 8.81 million shares representing 8.2362 and valued at over $359.76 million, while BLACKROCK INC. holds 8.0638 of the shares totaling 8.62 million with a market value of $352.23 million.
Avidity Biosciences Inc (RNA) Insider Activity
The most recent transaction is an insider sale by Gallagher Kathleen P., the company’s Chief Program Officer. SEC filings show that Gallagher Kathleen P. sold 5,875 shares of the company’s common stock on Apr 01 ’25 at a price of $27.83 per share for a total of $0.16 million. Following the sale, the insider now owns 50554.0 shares.
Avidity Biosciences Inc disclosed in a document filed with the SEC on Mar 20 ’25 that Hughes Steven George (Chief Medical Officer) sold a total of 9,578 shares of the company’s common stock. The trade occurred on Mar 20 ’25 and was made at $31.06 per share for $0.3 million. Following the transaction, the insider now directly holds 72850.0 shares of the RNA stock.
Still, SEC filings show that on Mar 20 ’25, Boyce Sarah (President and CEO) disposed off 31,540 shares at an average price of $31.06 for $0.98 million. The insider now directly holds 305,871 shares of Avidity Biosciences Inc (RNA).
